Drug Database
RI

rituximab (Rituxirel / Toritz)

✓ Approved

Reliance Life Sciences Private Limited · MS4A1 · 单克隆抗体

什么是 rituximab?

rituximab 是一种单克隆抗体,由Reliance Life Sciences Private Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intracerebral/cerebroventricular Injection、Intravenous (IV)、Subcutaneous Injection。

药物档案

商品名Rituxirel, Toritz
公司Reliance Life Sciences Private Limited
药物类别单克隆抗体, 抗体
分子靶点MS4A1
给药途径Injectable (Others), Intracerebral/cerebroventricular Injection, Intravenous (IV), Subcutaneous Injection
状态Approved

作用机制

分子靶点

rituximab 作用于 1 个分子靶点:

MS4A1membrane spanning 4-domains A1 (S7, B1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

rituximab 针对 8 个适应症,涉及 4 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-Hodgkin's lymphoma✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)B-cell lymphomaPreclinical
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Chronic lymphocytic leukaemiaPreclinical
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Mantle cell lymphomaPreclinical

注册免费账户还可查看另外 3 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedThrombosis journal2026-11-19

Adverse factors associated with mortality among patients with immune-mediated thrombotic thrombocytopenic purpura in Taiwan: a single-institute cohort study.

Lin Hsuan-Yu HY, Lin Ching-Yeh CY, Lin Jen-Shiou JS, Shih Yu-Hung YH et al.

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) in conjunction with a severe deficiency in ADAMTS13 activity. It remains uncertain which subgroups are at a higher risk of death for patients with iTTP in Taiwan, where therapeutic plasma exchange (TPE) is the primary treatment. This study was conducted to investigate the clinical characteristics, treatment outcomes, and mortality risk factors in patients with iTTP in Taiwan. Between 2012 and 2023, 22 patients with acute episodes of iTTP were enrolled. The clinical and laboratory findings at diagnosis, as well as the treatment strategy and outcomes, were retrospectively collected. The ADAMTS13 activities and anti-ADAMTS13 IgG levels were determined, using either a fluorescence resonance energy transfer (FRET)-based or an ELISA-based assay. Neutralizing autoantibodies against ADAMTS13 were determined by Bethesda methods. We enrolled 14 male and 8 female patients, with a median age of 61.5 years. All presented with microangiopathic hemolytic anemia and profound thrombocytopenia. Major and minor neurologic deficits were identified in 9 and 8 patients, respectively; serum creatinine levels exceeding 1.2 mg/mL were observed in seven cases. Elevated cardiac troponin-I levels were also found (in 11/11). At diagnosis, ADAMTS13 activities were less than 10%. Meanwhile, we confirmed the substantially high titers of autoantibodies against ADAMTS13. The regional incidence is estimated to be 0.73 per million person-years. The cardinal treatment strategy incorporated TPE and glucocorticoids. Only six patients received rituximab. Our approach led to a clinical response in 17 patients (77.2%), while the remaining five were refractory to treatment, which resulted in their death. Following the cessation of TPE, 13 patients sustained the response and obtained a clinical remission, eight of whom had an ADAMTS13 remission. However, four patients experienced exacerbations after initially responding to treatment. Additionally, three patients relapsed from their remissions. Mortality was associated with major neurologic impairment (p = 0.005), elevated lactate dehydrogenase (LDH) exceeding 5-fold (p = 0.039), and treatment-refractory cases (p < 0.001). The risk factors associated with mortality of iTTP patients in Taiwan are mainly consistent with those observed in larger cohorts. CCH IRB 240804.

PMID 43053037
阅读全文 →
PubMedFrontiers in immunology2026-11-18

Higher observed 12-month relapse-free survival with satralizumab than with rituximab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: a multicenter retrospective cohort study.

Lin Xiao X, Zhang Jicheng J, Chen Lei L, Deng Meiqun M et al.

Direct real-world comparisons of satralizumab and rituximab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder remain uncommon. We conducted a multicenter retrospective cohort study across eight hospitals in Fujian Province, China. Patients aged 12 years or older contributed treatment episodes beginning at the first verifiable administration of satralizumab or rituximab. Patients who changed therapy could contribute one episode to each treatment group, while uncertainty estimates accounted for patient-level clustering. The primary outcome was time to the first clinician-documented NMOSD relapse. Kaplan-Meier methods estimated 12-month relapse-free survival and its absolute between-treatment difference. Restricted mean relapse-free time, recurrent relapses, treatment-period safety events, and exploratory Expanded Disability Status Scale outcomes were also examined. Sensitivity analyses considered treatment switching, episode selection, calendar era, center composition, age restriction, and propensity-score overlap weighting. The cohort included 103 patients and 115 treatment episodes (50 satralizumab and 65 rituximab). First relapse within 12 months occurred in 1 satralizumab episode and 10 rituximab episodes. Twelve-month relapse-free survival was 98.0% (95% CI, 94.2-100.0%) with satralizumab and 84.6% (95% CI, 76.2-93.8%) with rituximab, an absolute difference of 13.44 percentage points (patient-clustered bootstrap 95% CI, 4.20-23.59). The direction was consistent across the principal unweighted sensitivity analyses. Corrected overlap weighting yielded a 5.28-percentage-point difference (95% CI, -11.69 to 21.21); limited common support, an effective rituximab sample size of 9.38, and appreciable patient influence made this an exploratory estimate. Infection rates were 18.2 and 14.7 events per 100 treatment-episode years, respectively (rate ratio, 1.24; 95% CI, 0.58-2.37), and one serious adverse event occurred in each group. Exploratory EDSS analyses did not identify a clear between-group difference. Satralizumab episodes had higher observed 12-month relapse-free survival than rituximab episodes in this cohort. The finding is a clinically relevant real-world comparison signal, while the treatment-specific contribution to the difference remains uncertain because treatment eras were separated, common support was limited, and satralizumab events were sparse.

PMID 43047378
阅读全文 →
PubMedClinical medicine insights. Arthritis and musculoskeletal disorders2026-11-18

Successful Use of Rituximab in Severe, Nonviral Cryoglobulinemic Vasculitis Complicated by Recurrent Infections and Macrophage Activation Syndrome: A Case Report.

Haddouche Assia A, Said Hiba Nait HN, Boudjelal Safa Ammar SA, Belamine Hind Arzour HA et al.

Nonviral mixed cryoglobulinemic vasculitis (CV) is a rare small-vessel vasculitis, frequently associated with connective tissue diseases. Its management is particularly challenging when severe systemic manifestations occur in patients with a high infectious risk or life-threatening complications. We report the case of a 42-year-old male with long-standing seropositive rheumatoid arthritis (RA) and secondary Sjögren syndrome (SS) presenting with severe CV (skin ulcers and multineuritis). Diagnosis was confirmed by the presence of type II mixed cryoglobulinemia, profound C4 consumption, and leukocytoclastic vasculitis on skin biopsy. Initial immunosuppressive therapy with cyclophosphamide was interrupted due to recurrent bacterial sepsis. Subsequent plasmapheresis was complicated by the development of macrophage activation syndrome (MAS), diagnosed based on HLH-2004 criteria. After stabilization with high-dose corticosteroids and intravenous immunoglobulin, rituximab (RTX) was introduced as salvage therapy. Following induction, a maintenance dose of 500 mg every 6 months was initiated to target both the high risk of vasculitis relapse and the rheumatoid arthritis. This approach led to durable clinical and biological remission with no recurrence of infection. This case highlights the challenges of managing nonviral CV in the context of autoimmune overlap and severe complications. Rituximab proved to be an effective and safe steroid-sparing strategy, even in a patient with a history of recurrent sepsis and MAS.

PMID 43048010
阅读全文 →
PubMedProceedings (Baylor University. Medical Center)2026-11-18

Immune checkpoint inhibitor-induced myocarditis, myositis, and myasthenia crisis overlap syndrome and mortality: a pooled case analysis.

Kolluri Madhumita M, Singh Kerry S KS, Hasan Mira M, Jailani Mohamed A MA et al.

Cancer patients on immune checkpoint inhibitors (ICIs) can rarely develop concurrent myocarditis, myositis, and myasthenia gravis, known as 3M syndrome. While a few reviews have been published to better understand the characteristics of 3M patients, no study to date has identified predictors of mortality in these patients. We systematically reviewed five databases for published cases of 3M syndrome from 2014 to 2024. Of 113 articles, we identified 153 adult 3M patients. For each patient, we recorded demographic data, ICI regimen, symptoms, diagnostic findings, treatment modalities, and discharge outcomes. Using multivariable logistic regression, we compared variables by mortality. Patients had a median age of 72 years, were predominantly male (73%), and were diagnosed with melanoma (32%). Pembrolizumab (30%) was the most common ICI. Common symptoms were dyspnea (59%), muscle weakness (59%), and dysphagia (37%), and most (73%) had varying degree ocular involvement. Troponin and creatinine kinase were elevated in nearly all patients. We identified three characteristics related to mortality: older age (P = 0.005), elevated liver enzymes (P = 0.02), and intubation (P = 0.002). We also identified factors related to survival: treatment with rituximab (P = 0.04) or abatacept (P = 0.02), elevated lactate dehydrogenase (P = 0.03), and tracheostomy (P = 0.046). Further investigation into potential predictors of survival in 3M syndrome patients, particularly regarding rituximab and abatacept use, may improve patient care and outcomes.

PMID 43049109
阅读全文 →
PubMedCureus2026-11-18

Bilateral Sensorineural Hearing Loss as the Sentinel Presentation of Granulomatosis With Polyangiitis.

Margolis Samuel S, Chan Chun Hin CH, Tran Wen-Ching WC

Granulomatosis with polyangiitis (GPA) is a systemic necrotizing granulomatous vasculitis classically involving the upper and lower respiratory tracts and kidneys. Timely diagnosis requires a high index of suspicion for the presenting symptoms. Otolaryngologic manifestations are commonly reported but most often involve the nasal and paranasal sinuses. Sensorineural hearing loss (SNHL) as the sole initial manifestation of GPA is uncommon and may contribute to diagnostic delay. We report a case of a 67-year-old male who presented with rapidly progressive bilateral SNHL that preceded pulmonary and renal manifestations by several months, during which the patient was treated for otitis externa and Eustachian tube dysfunction without improvement. Development of pulmonary symptoms prompted additional workup, which demonstrated markedly elevated cytoplasmic anti-neutrophil cytoplasmic antibody (c-ANCA) and proteinase 3-anti-neutrophil cytoplasmic antibody (PR3-ANCA), raising concern for GPA. Histopathology then confirmed the diagnosis. The patient was treated with high-dose corticosteroids and rituximab with serologic remission; however, his hearing loss was largely irreversible. This case highlights bilateral SNHL as an uncommon sentinel manifestation of GPA and emphasizes the importance of considering GPA in patients with unexplained rapidly progressive bilateral SNHL. Early recognition and prompt treatment may reduce irreversible injury.

PMID 43048753
阅读全文 →
PubMedBritish journal of clinical pharmacology2026-11-18

Population pharmacokinetics and exposure-response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial.

Olabode Damilola D, Zhou Diansong D, Siddiki Nurahamid N, Yang Jincheng J et al.

The phase 3 ECHO trial demonstrated superior progression-free survival (PFS) with acalabrutinib plus bendamustine-rituximab (BR) versus placebo plus BR in treatment-naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP-5862 (active metabolite) when administered with BR and evaluates exposure-response (efficacy/safety) relationships based on ECHO data. In ECHO, patients aged ≥65 years with TN MCL received BR plus acalabrutinib or placebo. Acalabrutinib (100 mg twice daily) or placebo was administered at study start until progressive disease or unacceptable toxicity. A pooled population PK analysis dataset included 975 patients for acalabrutinib and 580 patients for ACP-5862 from ECHO plus 10 clinical trials. Exposure-response analyses examined associations between exposure and PFS, best overall response (BOR), and adverse events (AEs) from ECHO. Population PK analysis showed that demographics (age, body weight, sex, ethnicity, race) and other intrinsic factors (mild or moderate renal impairment; mild or moderate hepatic impairment) had no meaningful effect on acalabrutinib/ACP-5862 exposure. No impact of co-administration with BR was observed on PK exposure. Exposure-efficacy analyses of ECHO data showed a flat relationship between acalabrutinib/ACP-5862 exposure and PFS and BOR. Exposure-safety analyses of ECHO data showed no clinically meaningful correlation between acalabrutinib/ACP-5862 exposure and selected safety outcomes (grade ≥3 AEs and events of clinical interest, AEs leading to dose modifications). This analysis supports a fixed 100 mg twice daily acalabrutinib dose, in combination with BR, as well-tolerated and efficacious in treatment of patients with TN MCL.

PMID 43045861
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多rituximab